Aklile Berhanu, PhD

Scientist
Genentech, Inc.

Disclosure: Genentech, Inc. (Individual(s) Involved: Self): Employee, Equity interest (Stock/Stock Options)

Presentation(s):

• 167 - A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple-ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients with staphylococcus Aureus Bacteremia Receiving Standard-of-care Antibiotics

  Oral Abstract